RxDoctor Payments Data

Fatoumata Diallo

Family · Bronx, NYNPI 1700289451

Payments from drug & device makers

$2,005in general payments, 2019–2025

Across 22 payments — averaging $91.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Cambridge Interventional LLC$329
  • Novartis$118
  • Bayer$52
  • Exact Sciences$26
  • Eisai Inc.$25
  • plus $72 from 4 others

What the payments were for

  • Travel & lodging$1,12856%
  • Food & beverage$87644%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic9$1,383
Cambridge Interventional LLC1$329
Novartis4$118
Bayer2$52
Exact Sciences1$26
Eisai Inc.1$25
Amneal Pharmaceuticals LLC1$20
AstraZeneca1$18
Insulet Corporation1$18
Aurinia Pharma U.S., Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,005 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$8,855
Medicare patients
30
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$128,377
JardianceEmpagliflozin66$59,099
FarxigaDapagliflozin Propanediol53$39,252
TrulicityDulaglutide35$38,406
MounjaroTirzepatide28$37,447
JanuviaSitagliptin Phosphate23$16,425
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$8,325
JanumetSitagliptin Phos/Metformin Hcl15$8,013
Levemir FlexpenInsulin Detemir25$4,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,307
Novolog FlexpenInsulin Aspart28$3,558
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic26$1,499
Repaglinide66$1,123
Ultra-Fine Short Pen NeedlePen Needle, Diabetic18$1,057
Levothyroxine Sodium77$758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$18$39,25253 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$20$75877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →